JP2006514621A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514621A5
JP2006514621A5 JP2004551490A JP2004551490A JP2006514621A5 JP 2006514621 A5 JP2006514621 A5 JP 2006514621A5 JP 2004551490 A JP2004551490 A JP 2004551490A JP 2004551490 A JP2004551490 A JP 2004551490A JP 2006514621 A5 JP2006514621 A5 JP 2006514621A5
Authority
JP
Japan
Prior art keywords
patient
hemorrhagic shock
administered
carbon monoxide
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004551490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514621A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/030956 external-priority patent/WO2004043341A2/en
Publication of JP2006514621A publication Critical patent/JP2006514621A/ja
Publication of JP2006514621A5 publication Critical patent/JP2006514621A5/ja
Withdrawn legal-status Critical Current

Links

JP2004551490A 2002-11-07 2003-09-30 出血性ショックの治療 Withdrawn JP2006514621A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42480402P 2002-11-07 2002-11-07
PCT/US2003/030956 WO2004043341A2 (en) 2002-11-07 2003-09-30 Treatment for hemorrhagic shock

Publications (2)

Publication Number Publication Date
JP2006514621A JP2006514621A (ja) 2006-05-11
JP2006514621A5 true JP2006514621A5 (https=) 2006-11-09

Family

ID=32312877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004551490A Withdrawn JP2006514621A (ja) 2002-11-07 2003-09-30 出血性ショックの治療

Country Status (13)

Country Link
US (1) US20040228930A1 (https=)
EP (1) EP1558084A4 (https=)
JP (1) JP2006514621A (https=)
CN (1) CN1719975A (https=)
AU (1) AU2003283982A1 (https=)
CA (1) CA2504604A1 (https=)
EA (1) EA200500782A1 (https=)
HR (1) HRP20050389A2 (https=)
MX (1) MXPA05004924A (https=)
NO (1) NO20052348L (https=)
PL (1) PL377733A1 (https=)
RS (1) RS20050344A (https=)
WO (1) WO2004043341A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
MXPA03012031A (es) * 2001-06-21 2005-07-01 Univ Yale El monoxido de carbono mejoraresultados en transplantes de tejido y organo y suprime apoptosis.
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
NZ534912A (en) * 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
RS91004A (sr) * 2002-04-15 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Postupci za lečenje ileusa
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
EP1499328B1 (en) * 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
JP4549847B2 (ja) 2002-05-17 2010-09-22 イエール ユニバーシティ 肝炎の治療方法
UA87438C2 (ru) * 2002-06-05 2009-07-27 Йельский Университет Способы лечения или профилактики рака, способ проведения хирургической операции по удалению рака и применения монооксида углерода
CN1674942A (zh) * 2002-06-21 2005-09-28 联邦高等教育系统匹兹堡大学 氧化氮、血红素加氧酶－1和血红素降解产物的药学用途
GB2395432B (en) 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
CN1901795B (zh) 2003-10-22 2014-03-26 弗雷德哈钦森癌症研究中心 用于在细胞，组织，器官，和有机体中诱导停滞的方法，组合物和装置
US7523752B2 (en) 2005-09-21 2009-04-28 Ino Therapeutics, Llc System and method of administering a pharmaceutical gas to a patient
US8893717B2 (en) 2005-09-21 2014-11-25 Ino Therapeutics Llc Systems and methods of administering a pharmaceutical gas to a patient
BRPI0616448A2 (pt) * 2005-09-30 2011-06-21 Ovation Pharmaceuticals Inc método de tratar e de profilaxia de pancreatite, método de induzir gene ho e método de tratamento ex vivo de pancreatite
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
JP5020525B2 (ja) * 2006-03-30 2012-09-05 財団法人生産開発科学研究所 配位子置換型輸液製剤
US7766857B2 (en) * 2006-08-21 2010-08-03 General Electric Company Non-invasive determination of cardiac output, gas exchange and arterial blood gas concentration
EP2514473A1 (en) * 2006-11-07 2012-10-24 The General Hospital Corporation Nitric oxide delivery device
EP2099439A2 (en) * 2006-12-06 2009-09-16 Alfama - Investigação E Desenvolvimento De Produto Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US8697747B2 (en) 2009-03-05 2014-04-15 The Uab Research Foundation Enhancing coagulation or reducing fibrinolysis
JP6118731B2 (ja) * 2011-01-14 2017-04-19 チルドレンズ ホスピタル ロサンゼルス 鎌状赤血球疾患を含む、疾患の治療のための一酸化炭素の溶液
EP2699242B1 (en) 2011-04-19 2017-11-01 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
CA2844660A1 (en) 2011-08-09 2013-02-14 Leo E. Otterbein Methods of treating dna damage
WO2020198604A1 (en) * 2019-03-28 2020-10-01 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods of treating and preventing systemic complications of acute illness

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5449665A (en) * 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) * 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) * 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
NZ262679A (en) * 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
ES2062943B1 (es) * 1993-03-23 1995-11-16 Uriach & Cia Sa J Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) * 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) * 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
JP3195363B2 (ja) * 1995-06-30 2001-08-06 ザイモジェネティクス，インコーポレイティド Ｐｄｇｆアンタゴニストとしての４−〔２−（ｎ−２−カルボキサミドインドール）アミノエチル〕ベンゼンスルホンアミドまたはスルホニル尿素
ES2267141T3 (es) * 1996-04-05 2007-03-01 The General Hospital Corporation Tratamiento de una hemoglobinopatia.
US6069132A (en) * 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
ATE358492T1 (de) * 1996-09-27 2007-04-15 Univ Columbia Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
US6203991B1 (en) * 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2812197B1 (fr) * 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2816212A1 (fr) * 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
BR0208012A (pt) * 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
US20030068387A1 (en) * 2001-03-30 2003-04-10 Roland Buelow Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1395241B9 (en) * 2001-05-25 2005-06-15 Medtronic, Inc. Implantable medical device with controllable gaseous agent release system
MXPA03012031A (es) * 2001-06-21 2005-07-01 Univ Yale El monoxido de carbono mejoraresultados en transplantes de tejido y organo y suprime apoptosis.
NZ534912A (en) * 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
BRPI0307673A2 (pt) * 2002-02-13 2016-11-08 Beth Israel Hospital métodos de tratar doença vascular.
RS91004A (sr) * 2002-04-15 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Postupci za lečenje ileusa
EP1499328B1 (en) * 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
WO2003088748A1 (en) * 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
JP4549847B2 (ja) * 2002-05-17 2010-09-22 イエール ユニバーシティ 肝炎の治療方法
UA87438C2 (ru) * 2002-06-05 2009-07-27 Йельский Университет Способы лечения или профилактики рака, способ проведения хирургической операции по удалению рака и применения монооксида углерода
CN1674942A (zh) * 2002-06-21 2005-09-28 联邦高等教育系统匹兹堡大学 氧化氮、血红素加氧酶－1和血红素降解产物的药学用途

Similar Documents

Publication Publication Date Title
JP2006514621A5 (https=)
Hole et al. Epidural versus general anaesthesia for total hip arthroplasty in elderly patients
McGowan Jr et al. Cardiopulmonary bypass significantly reduces surfactant activity in children
US4679555A (en) Method and apparatus for intrapulmonary delivery of heparin
JP4585765B2 (ja) 壊死性腸炎の治療方法
JPH0597683A (ja) 麻酔方法
JP2005530737A5 (https=)
Unger et al. Trypsin inhalations in respiratory conditions with thick sputum
Philip Supplemental medication for ambulatory procedures under regional anesthesia
Evans et al. Arterial occlusion after cannulation.
JPH01503146A (ja) 身体組織の治療方法および身体組織への医薬の投与方法
BRPI1008165B1 (pt) Uma combinação terapêutica compreendendo um surfactante pulmonar e um esteróide
Cunningham Oxygen Therapy by Means of Compressed Air.
DIAMANT et al. Laparoscopic sterilization with local anesthesia: complications and blood-gas changes
CN111265477B (zh) 一种卡络磺钠氯化钠注射液及其制备方法
Downing et al. IV doxapram hydrochloride and pulmonary complications after lower abdominal surgery
Jun et al. Influence of microcirculatory dysfunction on myocardial injury after cardiopulmonary resuscitation
Klein et al. Acute toxic methemoglobinemia caused by a topical anesthetic
Anand Complications associated with intermittent pneumatic compression devices
RU2190400C2 (ru) Способ лечения респираторного дистресс-синдрома
Klein A glossary of anesthesia and related terminology
Ueyama et al. Warning: carbon dioxide absorption capacity of Amsorb was unexpectedly low in low-flow anesthesia
Ahmed et al. Comparison of isofluraneand sevofluranein anesthesia for day case surgeries using classical laryngeal mask airway
Zaky et al. Use of Krypton-85 in the study of hypoxia in porto-pulmonary bilharziasis (schistosomiasis)
Renfrew et al. Severe hypertension following ephedrine administration in a patient receiving entacapone